Research Studies

Inflammatory Neuropathy Consortium

Investigator-Led International Research Studies Supported by the INC Network

  • Active (ongoing or in planning) at March 2022. Videos date from June 2021.
  • We do not list single-country studies, or clinical research studies sponsored by the pharmaceutical industry, although many INC members are participating in these. The most up-to-date list is at https://clinicaltrials.gov/
  • A summary of active clinical research trials in inflammatory neuropathy, aimed at patients, is given at Current Clinical Trials – GBS/CIDP Foundation International

IGOS  (International GBS Outcome Study)

Bart Jacobs (NL) et al.

Learn More

This has been an enormous effort involving 144 centers and 18 countries. In May 2021, the aimed number of 2000 inclusions was reached. Follow-up from previously included patients will continue until the last (3 year) follow-up visit of the last enrolled patients (May 2024).

The IGOS research program consists of 34 research projects in five different research domains: clinical, laboratory, prognostic, electrophysiological and treatment studies. Six studies have already been published, 6 have been submitted, 6 papers are in preparation and the data of 5 projects are currently being analysed.

The IGOS Consortium will continue to conduct further studies, including on genetics, pharmacokinetics, proteomics, outcome measures and new treatments.  A protocol for IGOS 2.0 is in development, which will focus on new research questions.

IMAGiNe (IgM Anti-MAG Peripheral Neuropathy: From Proper Assessment to Trial Needs)

Tatiana Hamadeh, Ingemar Merkies, Catharina Farber, Nicolette Notermans (NL).

Learn More

Prospective observational study including registry, biobanking and development of a disease specific Rasch-built patient-reported outcome measure (IgM anti-MAG paraproteinemic neuropathy: from proper assessment to trial needs).

Currently, 181 patients are included (from centers inNetherlands, USA, Spain, Italy, Serbia, Denmark) and ethical board approvals are pend-ing for other centers that have agreed to participate.


Filip Etimov (NL), Luis Querol (ES)

Learn More

International registry and biobank for CIDP. 

OPTIC Trial: Optimal Induction Treatment in CIDP

Filip Etimoc (NL) and Mike Lunn (UK)

Learn More

IVIg+placebo versus IVIg+methylprednisolone. 

Join a Special Interest Group